LG Chem Announces First Subject Enrolled in Phase 1 Clinical Trial of NASH New Drug

CAMBRIDGE, Mass.–(BUSINESS WIRE)–LG Chem recently announced the enrollment of first subject in Phase 1 clinical trial of LG203003, LG Chem’s second NASH (non-alcoholic steatohepatitis) drug in development.

Excerpt from the Press Release:

LG203003 received clearance from the U.S. Food and Drug Administration (FDA) in March 2022 for the Company’s Investigational New Drug (IND) application to conduct Phase 1 clinical trial in 88 subjects including healthy adults and patients with non-alcoholic fatty liver disease (NAFLD). First subject was dosed on July 6, 2022, and the trial will evaluate the safety, tolerability, as well as the pharmacokinetics (PK) and pharmacodynamics (PD) of LG203003.

NASH is the most advanced form of NAFLD (inflammation of liver caused by the build-up of extra fat in liver cells that is not caused by alcohol consumption), and it is a chronic, progressive disease characterized by fatty liver, liver cell injury and fibrosis. NASH is the major cause of liver cirrhosis, liver transplantation, and HCC (hepatocellular carcinoma) in western countries.

LG203003 is the second NASH compound in LG Chem Life Sciences’ pipeline, and it is formulated to suppress the accumulation of fat in liver cells by selectively impeding the activation of DGAT2 (diacylglycerol O-acyltransferase 2), a triglyceride synthetase, thus reducing liver cell damage. In various pre-clinical models, LG203003 showed to significantly decrease triglyceride, inflammation, and fibrosis in liver.

Click the button below to read the entire Press Release:

Continue Reading The Press Release